Ono Pharmaceutical Co Ltd
TSE:4528

Watchlist Manager
Ono Pharmaceutical Co Ltd Logo
Ono Pharmaceutical Co Ltd
TSE:4528
Watchlist
Price: 1 600 JPY -0.03%
Market Cap: 751.4B JPY
Have any thoughts about
Ono Pharmaceutical Co Ltd?
Write Note

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Ono Pharmaceutical Co Ltd

Revenue
484.3B JPY
Cost of Revenue
-119.2B JPY
Gross Profit
365.1B JPY
Operating Expenses
-246.3B JPY
Operating Income
118.8B JPY
Other Expenses
-23.7B JPY
Net Income
95.1B JPY

Margins Comparison
Ono Pharmaceutical Co Ltd Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
JP
Ono Pharmaceutical Co Ltd
TSE:4528
751.5B JPY
75%
25%
20%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-3%
-83%
-79%
US
Eli Lilly and Co
NYSE:LLY
756.3B USD
81%
35%
20%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
3%
-4%
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK
85%
44%
35%
US
Johnson & Johnson
NYSE:JNJ
349.7B USD
69%
28%
17%
US
Merck & Co Inc
NYSE:MRK
251.6B USD
77%
34%
19%
CH
Roche Holding AG
SIX:ROG
200.1B CHF
73%
32%
20%
UK
AstraZeneca PLC
LSE:AZN
162.1B GBP
82%
21%
13%
CH
Novartis AG
SIX:NOVN
171.5B CHF
75%
31%
35%
US
Pfizer Inc
NYSE:PFE
151.4B USD
71%
22%
7%
Country JP
Market Cap 751.5B JPY
Gross Margin
75%
Operating Margin
25%
Net Margin
20%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Operating Margin
-83%
Net Margin
-79%
Country US
Market Cap 756.3B USD
Gross Margin
81%
Operating Margin
35%
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Operating Margin
3%
Net Margin
-4%
Country DK
Market Cap 2.7T DKK
Gross Margin
85%
Operating Margin
44%
Net Margin
35%
Country US
Market Cap 349.7B USD
Gross Margin
69%
Operating Margin
28%
Net Margin
17%
Country US
Market Cap 251.6B USD
Gross Margin
77%
Operating Margin
34%
Net Margin
19%
Country CH
Market Cap 200.1B CHF
Gross Margin
73%
Operating Margin
32%
Net Margin
20%
Country UK
Market Cap 162.1B GBP
Gross Margin
82%
Operating Margin
21%
Net Margin
13%
Country CH
Market Cap 171.5B CHF
Gross Margin
75%
Operating Margin
31%
Net Margin
35%
Country US
Market Cap 151.4B USD
Gross Margin
71%
Operating Margin
22%
Net Margin
7%
No Stocks Found

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Ono Pharmaceutical Co Ltd Competitors

Country Company Market Cap ROE ROA ROCE ROIC
JP
Ono Pharmaceutical Co Ltd
TSE:4528
751.5B JPY
12%
10%
14%
13%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-441%
-47%
-108%
-64%
US
Eli Lilly and Co
NYSE:LLY
756.3B USD
66%
13%
33%
19%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK
89%
27%
75%
35%
US
Johnson & Johnson
NYSE:JNJ
349.7B USD
20%
8%
18%
13%
US
Merck & Co Inc
NYSE:MRK
251.6B USD
28%
11%
25%
20%
CH
Roche Holding AG
SIX:ROG
200.1B CHF
40%
13%
29%
22%
UK
AstraZeneca PLC
LSE:AZN
162.1B GBP
17%
6%
14%
12%
CH
Novartis AG
SIX:NOVN
171.5B CHF
45%
17%
24%
16%
US
Pfizer Inc
NYSE:PFE
151.4B USD
5%
2%
7%
8%
Country JP
Market Cap 751.5B JPY
ROE
12%
ROA
10%
ROCE
14%
ROIC
13%
Country JP
Market Cap 776 550.9T JPY
ROE
-441%
ROA
-47%
ROCE
-108%
ROIC
-64%
Country US
Market Cap 756.3B USD
ROE
66%
ROA
13%
ROCE
33%
ROIC
19%
Country UK
Market Cap 440.4B GBP
ROE
-4%
ROA
-2%
ROCE
2%
ROIC
2%
Country DK
Market Cap 2.7T DKK
ROE
89%
ROA
27%
ROCE
75%
ROIC
35%
Country US
Market Cap 349.7B USD
ROE
20%
ROA
8%
ROCE
18%
ROIC
13%
Country US
Market Cap 251.6B USD
ROE
28%
ROA
11%
ROCE
25%
ROIC
20%
Country CH
Market Cap 200.1B CHF
ROE
40%
ROA
13%
ROCE
29%
ROIC
22%
Country UK
Market Cap 162.1B GBP
ROE
17%
ROA
6%
ROCE
14%
ROIC
12%
Country CH
Market Cap 171.5B CHF
ROE
45%
ROA
17%
ROCE
24%
ROIC
16%
Country US
Market Cap 151.4B USD
ROE
5%
ROA
2%
ROCE
7%
ROIC
8%
No Stocks Found

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More
Back to Top